The JAK1/2 inhibitor ruxolitinib is clinically approved for myeloproliferative neoplasms and was shown to effectively impair repopulation of immunodeficient mice by self-renewing CML HSPCs, attributed to JAK/STAT5 inhibition primarily [94]. Here, JAK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.